Sangamo Therapeutics, Inc.
SGMO
$0.14
$0.000.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.55M | 32.88M | 81.71M | 63.76M | 57.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.55M | 32.88M | 81.71M | 63.76M | 57.80M |
| Cost of Revenue | 111.47M | 103.51M | 103.10M | 100.24M | 111.32M |
| Gross Profit | -71.92M | -70.63M | -21.39M | -36.48M | -53.52M |
| SG&A Expenses | 34.89M | 36.99M | 37.85M | 43.02M | 44.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 146.36M | 140.50M | 140.95M | 143.26M | 156.05M |
| Operating Income | -106.80M | -107.63M | -59.24M | -79.50M | -98.25M |
| Income Before Tax | -123.50M | -109.35M | -63.50M | -79.60M | -98.11M |
| Income Tax Expenses | -568.00K | -442.00K | -193.00K | -146.00K | -167.00K |
| Earnings from Continuing Operations | -122.93 | -108.91 | -63.31 | -79.45 | -97.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.93M | -108.91M | -63.31M | -79.45M | -97.94M |
| EBIT | -106.80M | -107.63M | -59.24M | -79.50M | -98.25M |
| EBITDA | -102.84M | -103.38M | -54.77M | -74.78M | -93.14M |
| EPS Basic | -0.44 | -0.44 | -0.28 | -0.38 | -0.51 |
| Normalized Basic EPS | -0.25 | -0.27 | -0.16 | -0.23 | -0.30 |
| EPS Diluted | -0.44 | -0.45 | -0.29 | -0.39 | -0.52 |
| Normalized Diluted EPS | -0.25 | -0.27 | -0.16 | -0.23 | -0.30 |
| Average Basic Shares Outstanding | 1.12B | 991.67M | 895.75M | 842.75M | 802.82M |
| Average Diluted Shares Outstanding | 1.12B | 991.67M | 901.73M | 848.73M | 808.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |